Glyxambi (empagliflozin and linagliptin) & nbsp;

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) July 2016 WARNINGS AND PRECAUTIONS Ketoacidosis (addition of the following sentence in first paragraph) Fatal cases of...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts